Capricor Therapeutics initiated with a Buy at Alliance Global Partners

Alliance Global Partners analyst Matthew Venezia initiated coverage of Capricor Therapeutics (CAPR) with a Buy rating and $20 price target adding a “Speculative” modifier to its rating, calling Capricor “a promising story with newly-added reagulatory risk but solid fundamentals,” which might make its relatively low current valuation “attractive to the right investor.” The firm’s 12- to 18-month valuation of Capricor shares is based on a sum-of-the parts analysis, including Deramiocel for DMD being valued at $15.00 per share, the analyst noted.